Investor directory

DaVita Venture Group

DaVita Venture Group, founded in 2020 and based in Denver, Colorado, serves as the investment arm of DaVita Inc. It focuses on partnering with healthcare innovators to enhance the lives of patients with kidney disease. The group aims to invest in, develop, and launch products and solutions that improve patient care, particularly in areas such as digital health, pharmaceuticals, and care delivery models. By targeting early-stage and later-stage companies, DaVita Venture Group seeks to support advancements that improve clinical outcomes, enhance patient experiences, and expand access to care, particularly through digital innovations and value-based treatment approaches.
http://www.davitaventuregroup.com
https://crunchbase.com/organization/davita-venture-group
https://linkedin.com/company/davita-venture-group
https://pitchbook.com/profiles/investor/435625-48
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=667587164

Amanda Kovach

Director, Partnerships and Corporate Development

Past deals in Dental

Pathalys Pharma

Seed Round in 2021
Pathalys Pharma is a clinical biopharmaceutical company focused on developing innovative therapeutics for late-stage chronic kidney disease. The company primarily aims to address the unmet medical need associated with secondary hyperparathyroidism (SHPT), a condition characterized by the overactivity of the parathyroid glands due to external diseases. Pathalys is developing upacicalcet, a novel calcimimetic designed to improve SHPT treatment in patients undergoing hemodialysis. Upacicalcet works by mimicking the action of calcium on tissues, activating the calcium-sensing receptor found in various human organs. This approach has the potential to enhance patient care for those suffering from end-stage chronic kidney disease.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.